WO2013151517A1 - Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique - Google Patents

Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique Download PDF

Info

Publication number
WO2013151517A1
WO2013151517A1 PCT/TR2013/000108 TR2013000108W WO2013151517A1 WO 2013151517 A1 WO2013151517 A1 WO 2013151517A1 TR 2013000108 W TR2013000108 W TR 2013000108W WO 2013151517 A1 WO2013151517 A1 WO 2013151517A1
Authority
WO
WIPO (PCT)
Prior art keywords
disintegrant
formulation according
pharmaceutical formulation
range
weight
Prior art date
Application number
PCT/TR2013/000108
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP13721136.3A priority Critical patent/EP2833872A1/fr
Publication of WO2013151517A1 publication Critical patent/WO2013151517A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil and clavulanic acid for use in the treatment of upper respiratory infections such as tonsillitis, sinusitis, pharyngitis, otitis media; lower respiratory tract infections such as uncomplicated upper and lower urinary tract infections, uncomplicated gonococcal urethritis, skin and soft tissue infections.
  • upper respiratory infections such as tonsillitis, sinusitis, pharyngitis, otitis media
  • lower respiratory tract infections such as uncomplicated upper and lower urinary tract infections, uncomplicated gonococcal urethritis, skin and soft tissue infections.
  • Said formulations are characterized in that they are in tablet form.
  • Cefpodoxime proxetil was first disclosed in the application numbered EP00491 18. It has been disclosed in said document that use of cefpodoxime proxetil is effective in treatment of infection related diseases caused by gram positive and gram negative bacteria.
  • Cefpodoxime proxetil is found in the form of granules for oral suspension comprising 40 mg / 5 ml, 50 mg / 5 ml and 100 mg / 5 ml cefpodoxime; powder for oral suspension comprising 40 mg / 5 ml cefpodoxime and tablet comprising 100 mg, 200 mg cefpodoxime on the market.
  • cefpodoxime proxetil The solubility of cefpodoxime in aqueous media is very low due to its hydrophobic characteristic.
  • formulations comprising cefpodoxime proxetil are compressed in tablet form, it has been observed that the active agent in said tablet form cannot be dissolved completely in the body fluid. Therefore, tablets comprising cefpodoxime proxetil cannot be easily and quickly dissolved in the body. This results in a decrease in the absorbance and the bioavailability of the drug and impedes the efficiency of the treatment.
  • a cephalosporin antibiotic such as cefpodoxime proxetil and a beta- lactamase inhibitor such as clavulanic acid are used together as a combination.
  • said low solubility and slow disintegration problems of formulations comprising cefpodoxime proxetil known in the state of the prior art, become more apparent in the presence of clavulanic acid as second active agent.
  • Clavulanic acid is known as a hygroscopic and moisture absorbent molecule.
  • tablet formulations comprising cefpodoxime proxetil and clavulanic acid combination dissolve easily in the body, disintegrate in a period of time less than 5 minutes and are quite stable in the case that formulations comprise a combination of disintegrant composed of at least two different disintegrants wherein ⁇ the amount of the first disintegrant is more than 5% and
  • the amount of the second disintegrant is less than 10% in proportion to total formulation amount.
  • the present invention relates to pharmaceutical tablet formulations comprising cefpodoxime proxetil and clavulanic acid combination characterized in that said formulation comprises a combination of disintegrant composed of at least two different disintegrants wherein
  • tablet formulations comprising cefpodoksime proxetil and clavulanic acid are characterized in that the amount of the first disintegrant is in the range of 5-20%, preferably in the range of 6-15% in proportion to total formulation weight.
  • tablet formulations comprising cefpodoxime proxetil and clavulanic acid are characterized in that the amount of the second disintegrant is in the range of 1 -10%, preferably in the range of 3-8% in proportion to total formulation weight.
  • the stability problems observed in cefpodoxime proxetil and clavulanic acid formulations decrease solubility of the drug in the body hence totality of the drug is not absorbed. This case leads to low bioavailability of the drug and low efficiency of the treatment.
  • the ratio of the first disintegrant to second disintegrant used in said formulations should be optimized. Accordingly, during the studies conducted for solving this problem, the inventors have found that if the ratio of the first disintegrant to the second disintegrant in the formulations prepared in accordance with the present invention is in the range of 5: 1 to 1 :5, preferably in the range of 4: 1 to 1 :3 by weight, more stabile and more soluble dosage forms in the body are obtained.
  • the ratio of the first disintegrant to the second disintegrant is in the range of 5: 1 to 1 :5, preferably in the range of 4: 1 to 1 :3 by weight.
  • the first disintegrant can be selected from a group comprising croscarmellose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, methylcellulose and/or combinations thereof.
  • the first disintegrant is croscarmellose calcium.
  • the second disintegrant is selected form group comprising carboxymethyl cellulose sodium, microcrystalline cellulose, hydroxypropyl cellulose, methylcellulose, starch and/or combinations thereof.
  • the second disintegrant is starch.
  • the ratio of croscarmellose calcium to starch can be in the range of 5: 1 to 1 :5, preferably in the range of 4: 1 to 1 :3 by weight.
  • cefpodoxime proxetil formulations Another problem observed in cefpodoxime proxetil formulations is the formation of aggregates during the preparation of the tablet form. If these aggregates are not eliminated, they prevent the formation of a homogenous mixture and destroy the uniform distribution of the active agent in the formulation. Studies conducted for solving said problem showed that not only the ratio of the disintegrants to each other but also the amount of cefpodoxime proxetil in proportion to the amount of disintegrant combination plays an important role in preparation of said formulations.
  • the inventors have found out that if the ratio of cefpodoxime proxetil to the disintegrant combination is in the range of 6: 1 to 1 :6, preferably 3:1 to 1 :3 by weight, no agglomeration is observed and the uniform distribution of the active agent is can be provided.
  • the ratio of cefpodoxime proxetil to the disintegrant combination is in the range of 6: 1 to 1 :6, preferably 3:1 to 1 :3 by weight.
  • Clavulanic acid comprised in the pharmaceutical formulations of the present invention can be in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, racemates, organic salts, inorganic salts and free base form or combinations thereof in respect to its chemical structure; in crystalline, amorphous form or combinations thereof in respect to its polymorphic structure.
  • clavulanic acid used as second active agent is in the potassium salt form.
  • the pharmaceutical formulation of the present invention comprising cefpodoxime proxetil and clavulanic acid can comprise at least one excipient selected form a group comprising antiadherant, glidant, diluent, surfactant, lubricant, humectant and film-coating agent in addition to the disintegrant combination.
  • the antiadherant that can be used in the pharmaceutical formulations of the present invention comprising cefpodoxime and clavulanic acid can be selected from a group comprising talc, starch, colloidal starch, leucine, sodium sulfite, stearates and/or combinations thereof.
  • the glidant that can be used in the pharmaceutical formulations of the present invention comprising cefpodoxime and clavulanic acid can be selected from a group comprising magnesium silicate, silicon dioxide, colloidal silicon dioxide, starch, talc, tribasic calcium phosphate and/or combinations thereof.
  • the diluent that can be used in the pharmaceutical formulations of the present invention comprising cefpodoxime and clavulanic acid can be selected from a group comprising D- mannitol, xylitol, microcrystalline cellulose, crospovidon, dibasic calcium phosphate anhydrous, lactose, starch, maltose, dextrin, maltodextrin, magnesium carbonate, talc and/or combinations thereof.
  • the surfactant that can be used in the pharmaceutical formulations of the present invention comprising cefpodoxime and clavulanic acid can be selected from a group comprising cetrimide, docusate sodium, glycerol monooleate, sorbital esters and sodium lauryl sulfate and/or combinations thereof.
  • the lubricant that can be used in the pharmaceutical formulations of the present invention can be selected from a group comprising calcium stearate, magnesium stearate, sodium stearyl sulphate fumarate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate and/or combinations thereof.
  • the humectant that can be used in the pharmaceutical formulations of the present invention can be selected from a group comprising silica, colloidal silica, magnesium trisilicate, powder cellulose, magnesium oxide, calcium silicate, starch, microcrystalline cellulose and talc and/or combinations thereof.
  • the ratio of potassium clavulanate to humectant is 1 : 1.
  • the film coating agent that can be used in the pharmaceutical formulations of the present invention can be selected from a group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin, hydroxypropyl cellulose and/or combinations thereof.
  • a film coating agent marketed under the trademark of Opadry Yellow can be used.
  • the pharmaceutical formulation of the present invention can be prepared in any tablet form such as conventional tablet, effervescent tablet, effervescent granule, effervescent dry powder, film coated tablet, enterically coated tablet, prolonged release tablet, modified release tablet, delayed release tablet.
  • the pharmaceutical formulation of the present invention is preferably in the form of film coated tablet.
  • the pharmaceutical formulation of the present invention can comprise cefpodoxime proxetil in the range of 5-70%, preferably 10- 60%, more preferably 20-50%.
  • the pharmaceutical formulation of the present invention can comprise the mixture of potassium clavulanate-humectant in the range of 10-70% by weight.
  • the pharmaceutical formulation of the present invention comprises 5-70% cefpodoxime proxetil, 10-70% potassium clavulanate-humectant mixture, 1-30% disintegrant, 0.5-2.5% surfactant, 5-25% diluent, 0.1 -2% antiadherant, 0.1-2% glidant, 0.1-2% lubricant, 0.5-3.5% film coating agent.
  • the preparation method of the pharmaceutical formulation of the present invention preferably involves the following steps:
  • Step IV Coating the tablet form obtained in Step IV with a coating colution comprising a film- coating agent.
  • the pharmaceutical formulation of the present invention can be used in the manufacturing of a drug for use in the treatment of upper respiratory infections such as tonsillitis, sinusitis, pharyngitis, otitis media; lower respiratory tract infections such as uncomplicated upper and lower urinary tract infections, uncomplicated gonococcal urethritis, skin and soft tissue infections.
  • upper respiratory infections such as tonsillitis, sinusitis, pharyngitis, otitis media
  • lower respiratory tract infections such as uncomplicated upper and lower urinary tract infections, uncomplicated gonococcal urethritis, skin and soft tissue infections.
  • Example I Tablet formulation comprising cefpodoxime proxetil and clavulanic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur des formulations pharmaceutiques comprenant du cefpodoxime proxétil et de l'acide clavulanique destinées à être utilisées dans le traitement d'infections des voies respiratoires supérieures telles qu'une amygdalite, une sinusite, une pharyngite, une otite moyenne ; d'infections des voies respiratoires inférieures telles que des infections des voies urinaires supérieure et inférieure non compliquées, une urétrite gonococcique non compliquée et d'infections cutanées et des parties molles. Lesdites formulations sont caractérisées en ce qu'elles sont sous forme de comprimés.
PCT/TR2013/000108 2012-04-04 2013-04-03 Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique WO2013151517A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13721136.3A EP2833872A1 (fr) 2012-04-04 2013-04-03 Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/03837 2012-04-04
TR201203837 2012-04-04

Publications (1)

Publication Number Publication Date
WO2013151517A1 true WO2013151517A1 (fr) 2013-10-10

Family

ID=48325848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000108 WO2013151517A1 (fr) 2012-04-04 2013-04-03 Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique

Country Status (2)

Country Link
EP (1) EP2833872A1 (fr)
WO (1) WO2013151517A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049118A2 (fr) 1980-09-30 1982-04-07 Sankyo Company Limited Dérivés de céphalosporines, leur préparation et compositions les contenant
WO1998001114A1 (fr) * 1996-07-03 1998-01-15 Yamanouchi Europe B.V. Granules destines a la preparation de compositions a haut pouvoir de desintegration et de dissolution, a teneur elevee en medicament
WO2011152807A1 (fr) * 2010-06-03 2011-12-08 Bilgic Mahmut Préparations pharmaceutiques comprenant du cefpodoxime proxetil et de l'acide clavulanique
WO2011152808A1 (fr) * 2010-06-03 2011-12-08 Mahmut Bilgic Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique
WO2012060786A2 (fr) * 2010-11-05 2012-05-10 Mahmut Bilgic Formulations de proxétil cefpodoxime comprenant un agent de viscosité

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049118A2 (fr) 1980-09-30 1982-04-07 Sankyo Company Limited Dérivés de céphalosporines, leur préparation et compositions les contenant
WO1998001114A1 (fr) * 1996-07-03 1998-01-15 Yamanouchi Europe B.V. Granules destines a la preparation de compositions a haut pouvoir de desintegration et de dissolution, a teneur elevee en medicament
WO2011152807A1 (fr) * 2010-06-03 2011-12-08 Bilgic Mahmut Préparations pharmaceutiques comprenant du cefpodoxime proxetil et de l'acide clavulanique
WO2011152808A1 (fr) * 2010-06-03 2011-12-08 Mahmut Bilgic Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique
WO2012060786A2 (fr) * 2010-11-05 2012-05-10 Mahmut Bilgic Formulations de proxétil cefpodoxime comprenant un agent de viscosité

Also Published As

Publication number Publication date
EP2833872A1 (fr) 2015-02-11

Similar Documents

Publication Publication Date Title
EP2528594B1 (fr) Formulations effervescentes contenant de la céphalosporine de deuxième génération
EP3417861B1 (fr) Composition pharmaceutique contenant un inhibiteur de janus kinase (jak) ou un sel pharmaceutiquement acceptable de celui-ci
US20160346207A1 (en) Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists
JP2010522692A (ja) ベンズイミダゾール−７−カルボキシレート誘導体およびｐＨ調整剤を含有する固形医薬組成物
EP2366379A1 (fr) Forme de cefdinir avec taux de dissolution amélioré
EP2568959A2 (fr) Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération
WO2011142730A1 (fr) Composition pharmaceutique comprenant la céfixime et un composé dérivé de l'acide clavulanique
EP2515850B1 (fr) Compositions pharmaceutiques comprenant cefdinir comme principe
WO2012060786A2 (fr) Formulations de proxétil cefpodoxime comprenant un agent de viscosité
EP2906203B1 (fr) Formulation effervescente de cefdinir
WO2011129792A1 (fr) Formulations dispersibles dans l'eau comprenant le cefpodoxime proxétil
EP2608776A2 (fr) Préparations de cefpodoxime proxétil
WO2011093828A2 (fr) Formes posologiques solides comprenant du cefprozil
WO2011093829A1 (fr) Compositions effervescentes comprenant du cefixime et de l'acide clavulanique comme principes actifs
EP2833872A1 (fr) Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique
EP2515859A1 (fr) Formulation effervescente à dispersion rapide
WO2017037645A1 (fr) Formulations pharmaceutiques stables de tériflunomide
EP2575777A1 (fr) Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique
WO2011152805A2 (fr) Composition pharmaceutique comprenant de l'acide clavulanique et du cefpodoxime proxétil
WO2012060787A1 (fr) Comprimés contenant du cefdinir
KR102231289B1 (ko) 고함량 콘드로이틴설페이트 약학 제제 및 이의 제조방법
WO2014123500A1 (fr) Formulations pharmaceutiques contenant du cefpodoxime proxétil et de l'acide clavulanique
JP2007297348A (ja) エバスチンを含有する錠剤
EP4026540A1 (fr) Comprimé revêtu d'un film comprenant de l'apixaban
WO2012060789A2 (fr) Procédé de production de formulations de cefdinir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13721136

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013721136

Country of ref document: EP